June 21 (Reuters) - The U.S. Food and Drug Administration has approved Bristol Myers Squibb's combination therapy for treating colorectal cancer patients with a specific gene mutation, the health regulator's website showed on Friday. (Reporting by Christy Santhosh, Unnamalai L and Puyaan Singh in Bengaluru; Editing by Shilpi Majumdar)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
41.9 USD | -1.42% | +1.91% | -18.49% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.49% | 86.15B | |
+54.97% | 811B | |
+43.62% | 640B | |
-7.12% | 353B | |
+17.91% | 333B | |
+8.56% | 302B | |
+16.30% | 246B | |
+2.41% | 225B | |
+12.47% | 218B | |
+8.63% | 168B |
- Stock Market
- Equities
- BMY Stock
- News Bristol-Myers Squibb Company
- US FDA approves Bristol Myers' colorectal cancer therapy